- |||||||||| chloroquine phosphate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. (Pubmed Central) - Oct 7, 2020
Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.
- |||||||||| Review, Journal: Diagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19). (Pubmed Central) - Oct 7, 2020
This review is aimed to collect and summarize a list of drugs used to treat COVID-19 for instance, dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide, and ivermectin. However, some of these drugs are not effective and suspended by the WHO (World Health Organization).
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. (Pubmed Central) - Oct 7, 2020
Multivariate Cox regression analysis revealed that male gender (hazard ratio [HR], 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] COVID-19- What Makes the UK Recovery Trial More Pragmatic THAN the Discovery Trial? () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1788;
Targeting 2,100 patients, the interventions in the DisCoVeRy trial included remdesivir, lopinavir-ritonavir, lopinavir-ritonavir-interferon beta, and hydroxychloroquine...The preliminary results of the RECOVERY trial were published on June 5th, 2020, while discovery has failed to recruit patients. CONCLUSIONS : Unlike the DisCoVeRy trial that was a perfect academic trial but infeasible, the RECOVERY trial prioritized feasibility and flexibility appropriately in the context of COVID-19 emergency to inform the control of mortality and rational use of scarce resources.
- |||||||||| [VIRTUAL] COVID-19- A Systematic Review of Chinese Clinical Guidelines () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1778;
Such endeavors secured China to react and coordinate all the available resources to cope with COVID-19 promptly and efficiently. These guidelines may have been insufficiently disseminated but led to widening CQ use across the world.
- |||||||||| [VIRTUAL] Review the Use of Antivirus for COVID19 Treatment in Indonesia () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1707;
Antiviral in the Covid19 Drug Information Laboratory in Indonesia are Lopinavir/Ritonavir, Favipiravir, Remdemsivir, Oseltamivir, Chloroquine Phosphate and Hydroxychloroquine Phosphate...Chloroquine, Hidroxychloroquine and Remdesivir effectively control the SARS-CoV2 virus invitro...It is supported by a safety profile. In a pandemic situation and the absence of a specific antivirus, the use of the six antiviruses can be done and can be useful.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, ibuprofen / Generic mfg.
[VIRTUAL] Evidence Summaries of Medicines USED for the Treatment of COVID-19- Ukrainian Information Platform () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1055;
Currently, the information resource covers 6 main topics with overall 19 summaries: antiseptics, antipyretics (ibuprofen, paracetamol, acetylsalicylic acid), antivirals (remdesivir, lopinavir/ritonavir, favipiravir), medicines that affect the immune response (tocilizumab, hydroxychloroquine, intravenous immunoglobulin (IVIG)), antibiotics and medicines for non-communicable diseases (treatment of diabetes, cardiovascular disease, oncology)... This project supported synthesis of information andevidence development for treatment of COVID-19 based on the international practice and highlighted importance of HTA use in the healthcare system in Ukraine for the achieving highest value for patients.
- |||||||||| remdesivir / Generic mfg., hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
[VIRTUAL] COVID-19- Why Solidarity and Discovery Trials MAY Fail to Bring Informative and Timely Results? () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_662;
CONCLUSIONS : From the logistic perspective, both trials lacked the resources to secure aligned and high-quality implementation. This review called for a pandemic task force with operational experts from the front-line of COVID-19 treatment to inform policymakers to make pragmatic and effective decisions when launching joined effort for trials.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Retrospective data, Journal: nImpact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time. (Pubmed Central) - Oct 3, 2020
To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections. The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents.
- |||||||||| hydroxychloroquine / Generic mfg.
Biomarker, Retrospective data, Journal: Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. (Pubmed Central) - Oct 3, 2020
In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacologic therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically a higher neutrophil-to-lymphocyte ratio, are conditions under which QTc interval monitoring should be particularly careful.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19. (Pubmed Central) - Oct 3, 2020
Likewise, vaccines against SARS-CoV-2 are being developed and tested, including mRNA, non-replicating viral vector, DNA, protein subunit candidate vaccines, etc. Although some early-stage clinical trials and studies on these drugs and vaccines have shown positive results, definitive and conclusive results are yet to be obtained. Keywords: COVID-19; antiviral drugs; COVID-19 treatment; COVID-19 vaccine; SARS-CoV-2.
- |||||||||| chloroquine phosphate / Generic mfg., Doburan (dobutamine) / VHB Life Sciences, lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). (Pubmed Central) - Oct 2, 2020
She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization. This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia.
- |||||||||| hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. (Pubmed Central) - Oct 2, 2020
No abstract available We found a high mortality in the first 100 patients diagnosed with COVID-19 at our institution, associated with advanced age and the presence of serious underlying diseases.
- |||||||||| Clinical, Clinical protocol, Journal: Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. (Pubmed Central) - Oct 2, 2020
The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%)...There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations...This study showed that COVID-19 protocols varied widely in several aspects (antiviral treatment, corticosteroids, anakinra, and anticoagulation for high risk of thrombosis or critical situation). Rigorous randomized clinical trials on the proposed treatments are needed to provide consistent evidence.
- |||||||||| ritonavir / Generic mfg.
PK/PD data, Journal: Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. (Pubmed Central) - Oct 1, 2020
A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted), and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval...Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin, and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC...This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. (Pubmed Central) - Oct 1, 2020
Future studies should focus on EC values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials. No abstract available
- |||||||||| favipiravir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open, Combination therapy: FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals (clinicaltrials.gov) - Sep 30, 2020
P2, N=240, Recruiting,
This review will continuously inform best practice in treatment and clinical research of COVID-19. Not yet recruiting --> Recruiting
- |||||||||| efavirenz / Merck (MSD), Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer. (Pubmed Central) - Sep 30, 2020
Both EFV and LPV/r exert double-edged oncogenic effects on MRC-5 and A549 lung cells, acting to either promote cell proliferation or to enhance apoptosis. This is affected by EFV and LPV/r altering cell cycle progression, with a significant S-phase arrest, this being an indication of cellular stress, cytotoxicity, and DNA damage within the cell.
- |||||||||| Clinical, Journal: Encephalopathy in COVID-19 patients; viral, parainfectious, or both? (Pubmed Central) - Sep 30, 2020
He had received combination treatment with interferon beta 1b and lopinavir/ritonavir...Patient 2 recovered with no specific treatment. These cases illustrate the need to understand the full spectrum of encephalopathy associated with COVID-19 so as to better guide its management.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial suspension, Trial primary completion date: OUTCOV: OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (clinicaltrials.gov) - Sep 28, 2020
P3, N=640, Suspended,
A NLME model for analysing viral pharmacodyamics in trials has been established. Recruiting --> Suspended | Trial primary completion date: Aug 2020 --> Dec 2020
- |||||||||| Clinical, Review, Journal: Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. (Pubmed Central) - Sep 26, 2020
Umifenovir (Arbidol) was associated with reduction in mortality in few studies. Overall, until now, U.S. Food and Drug administration issued only emergency use authorization to remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. (Pubmed Central) - Sep 26, 2020
97.5% received lopinavir/ritonavir-based regimens...This study demonstrates high levels of NRTI and NNRTI resistance and moderate levels of PI resistance in people receiving PI/r-based second-line ART in Namibia. Findings underscore the need for objective and inexpensive measures of adherence to identify those in need of intensive adherence counselling, routine viral load monitoring to promptly detect virological failure, and HIVDR genotyping to optimize selection of third-line drugs in Namibia.
- |||||||||| chloroquine phosphate / Generic mfg., hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. (Pubmed Central) - Sep 25, 2020
Ocular side effects have also been reported with other investigational drugs like lopinavir-ritonavir, interferons, and interleukin-1 and interleukin-6 inhibitors. The aim of this review was to summarize ophthalmological implications of SARS-CoV-2 infection to serve as a reference for eye care and other physicians for prompt diagnosis and management.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Qt interval measurement with portable device during covid-19 outbreak. (Pubmed Central) - Sep 25, 2020
All patients with drug induced QT prolongation corrected the QT interval following the indications of the protocol, and no patients died of arrhythmic causes after its implementation. In our experience, a protocol for the electrocardiographic monitoring of these patients minimizes the risk of iatrogenic QT interval prolongation and consequently reduces sudden death events, and for that purpose, portable devices like the one used in this protocol may constitute a useful tool to minimize the contact with such patients.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. (Pubmed Central) - Sep 24, 2020
Clinical course was summarized, including requirement for supplemental oxygen and intensive care and use of empirical treatment with lopinavir-ritonavir...Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection. Some patients required supplemental oxygen and had variable clinical outcomes following treatment with an antiretroviral agent.
- |||||||||| hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19. (Pubmed Central) - Sep 23, 2020
Antiviral therapy using LPV/r or chloroquine seemed not to improve the prognosis or shorten the clinical course of COVID-19. Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation.
|
